Compare iShares MSCI ACWI ETF (ACWI) vs Amphastar Pharmaceuticals Inc (AMPH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI ACWI ETF vs Amphastar Pharmaceuticals Inc — how do they compare? iShares MSCI ACWI ETF trades at $160.86, while Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M). The key difference: iShares MSCI ACWI ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ACWI | AMPH | |
|---|---|---|
52-Week High | $161.44 | $30.81 |
52-Week Low | $131.51 | $16.87 |
Market Cap | — | $863.95M |
Sector | — | Health |
Enterprise Value | — | $1.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACWI (iShares MSCI ACWI ETF) trades at $161.44, up 0.84% with a bullish technical signal from moving averages, though oscillators show caution. The ETF benefits from strong global earnings growth and a forward P/E of 15.5x as of Seeking Alpha on July 7, 2026. Recent institutional activity includes Bank of New York Mellon adjusting its stake, reflecting ongoing investor interest in global equity exposure, particularly in technology sectors.
The outlook for ACWI is supported by robust EPS growth and technical momentum, but risks include market volatility and sector concentration. Investors may find opportunity in its diversified global holdings, though overbought conditions near resistance at $162 warrant monitoring for pullbacks to support at $160.
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI ACWI ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization index designed to measure the combined equity market performance of developed and emerging markets countries.
Read more on ACWI →About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →
